Browsing by Yonsei Author : Cho, Byoung Chul

eperson profile image
Name:
Cho, Byoung Chul [조병철]
orcid http://orcid.org/0000-0002-5562-270X
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (7401747804)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 385

This table browses all dspace content
Issue DateTitleJournal Title
2024Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study FUTURE ONCOLOGY
2024NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations CANCER DISCOVERY
2024ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER TrialCLINICAL CANCER RESEARCH
2024Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3JOURNAL OF THORACIC ONCOLOGY
2024Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma ESMO OPEN
2024Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study BMC MEDICINE
2024Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung CancerNEW ENGLAND JOURNAL OF MEDICINE
2024Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer ONCOLOGIST
2024Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutationLUNG CANCER
2024Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLCNEW ENGLAND JOURNAL OF MEDICINE
2024Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea Lung Cancer : targets and therapy
2024BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2024Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAANNALS OF ONCOLOGY
2024Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2024D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities CANCER DISCOVERY
2024Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunitiesLUNG CANCER
2024Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerCLINICAL CANCER RESEARCH
2024A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS studyCancer Treatment and Research Communications
2024Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma CANCER RESEARCH COMMUNICATIONS
2024Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study BMC CANCER
2024Novel allosteric glutaminase inhibitors with macrocyclic structure activity relationship analysis (part 2)BULLETIN OF THE KOREAN CHEMICAL SOCIETY
2024ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).JOURNAL OF CLINICAL ONCOLOGY
2024A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12) ONCOIMMUNOLOGY
2024Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy response THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2024A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study CLINICAL LUNG CANCER
2024Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER studyHEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
2024Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)JOURNAL OF CLINICAL PHARMACOLOGY
2024Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study CANCER MEDICINE
2024Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLCCLINICAL CANCER RESEARCH
2024Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterationsLUNG CANCER
2024Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201 LUNG CANCER
2024Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types FRONTIERS IN IMMUNOLOGY
2024Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study LUNG CANCER
2024Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLCJOURNAL OF THORACIC ONCOLOGY
2024Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC JTO Clinical and Research Reports
2024CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production FRONTIERS IN IMMUNOLOGY
2024Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay CANNALS OF ONCOLOGY
2024Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells NATURE
2024Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trialLUNG CANCER
2024Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report JTO Clinical and Research Reports
2024Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing PLOS ONE
2024Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer LUNG CANCER
2024Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 TrialJOURNAL OF CLINICAL ONCOLOGY
2024Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study ANNALS OF ONCOLOGY
2024Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset CANCER RESEARCH AND TREATMENT
2024Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical TrialJOURNAL OF CLINICAL ONCOLOGY
2024Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2024Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific ORAL ONCOLOGY
2024Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung CancerNEW ENGLAND JOURNAL OF MEDICINE
2024Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudyTHYROID

Browse

Links